Predictors of persistent opioid use following curative-intent radiation for head and neck cancer.

A Alec Kotler (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) O Om Desai (Research Group for Organic Chemistry and Biocatalysis Faculty of Chemistry Bielefeld University Universitätsstraße 25 33615 Bielefeld Germany) K Kevin Agner (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) J Jacob Wells (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) M Matthew Nguyen (1Montefiore Einstein, Bronx, United States) D Darien Reed (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) K Krithik Tella (The Ohio State University, Columbus, OH) D Daniel Álvarez (Department of Biology, University of Fribourg) A Andrew Koempel (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) P Priyanka Bhateja (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) E Emile Gogineni (The Ohio State University Comprehensive Cancer Center - The James Cancer Hospital and Solove Research Institute, Columbus, OH) S Sujith Baliga (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) D David Joseph Konieczkowski (The Ohio State University Comprehensive Cancer Center - The James Cancer Hospital and Solove Research Institute, Columbus, OH) S Sachin R. Jhawar J John C. Grecula (The Ohio State University Comprehensive Cancer Center - The James Cancer Hospital and Solove Research Institute, Columbus, OH) L Lauren Miller M Marcelo Raul Bonomi (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) D Dukagjin Blakaj (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH) S Sung Jun Ma (The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH)

Abstract

e18099 Background: Head and neck cancer (HNC) patients often experience pain from intense radiation treatment. Opioids work well to minimize this side effect. However, persistent use during and after treatment can cause significant health problems. There is little data in the literature that can help predict a predisposition for prolonged opioid use in HNC patients who receive radiation. Analysis of such data could aid HNC providers and patients in making appropriate and informed pain management choices. Methods: This study reviewed a retrospective single-institution cohort of HNC patients treated with definitive radiation, chemoradiation, or induction chemotherapy followed by chemoradiation between October 2011 and December 2023. Multivariable logistic regression was used to identify factors associated with continued opioid use at three and six months following radiation. Fine-Gray competing-risk regression evaluated time to first opioid use among opioid-naïve patients. Results: Among 789 patients (81% male; median age 61 years), 95.1% received opioids within 6 months of diagnosis. 40% of these patients continued opioid use three months after treatment and 15% continued use six months following treatment. Patients who continued opioid user at three months post treatment did so independently of other factors that were evaluated such as former smoking, radiation treatment alone, prior opioid use, and palliative medicine involvement. Continued use after six months was associated with opioid use at three months and palliative medicine involvement. Thin weight status and palliative medicine involvement was associated with earlier opioid initiation, while treatments of induction chemotherapy and radiation alone were associated with delayed opioid initiation. Interestingly, patients with advanced disease when care began, had lower long-term opioid risk. Conclusions: When HNC patients get curative radiation treatment, long-term opioid use is common. Early identification of high-risk patients may facilitate targeted opioid treatment strategies that help with pain management while also reducing long-term opioid dependence.

Article Details

Volume / Issue Vol. 44, Issue 16_suppl
Published June 01, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (19)

A

Alec Kotler

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

O

Om Desai

Research Group for Organic Chemistry and Biocatalysis Faculty of Chemistry Bielefeld University Universitätsstraße 25 33615 Bielefeld Germany

K

Kevin Agner

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

J

Jacob Wells

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

M

Matthew Nguyen

1Montefiore Einstein, Bronx, United States

D

Darien Reed

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

K

Krithik Tella

The Ohio State University, Columbus, OH

D

Daniel Álvarez

Department of Biology, University of Fribourg

A

Andrew Koempel

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

P

Priyanka Bhateja

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

E

Emile Gogineni

The Ohio State University Comprehensive Cancer Center - The James Cancer Hospital and Solove Research Institute, Columbus, OH

S

Sujith Baliga

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

D

David Joseph Konieczkowski

The Ohio State University Comprehensive Cancer Center - The James Cancer Hospital and Solove Research Institute, Columbus, OH

S

Sachin R. Jhawar

J

John C. Grecula

The Ohio State University Comprehensive Cancer Center - The James Cancer Hospital and Solove Research Institute, Columbus, OH

L

Lauren Miller

M

Marcelo Raul Bonomi

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

D

Dukagjin Blakaj

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH

S

Sung Jun Ma

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH